In addition, Novartis participates in Europe’s largest public-private initiative, IMI iPiE (Innovative Medicines Initiative on the Intelligent Assessment of Pharmaceuticals in the Environment), which is developing a framework to identify the potential risk of pharmaceuticals to the natural environment and thus directs the way to perform an appropriate hazard assessment.